Bangalore, June 4, 2007: TaiGen Biotechnology, based out of Taipei, Taiwan, has declared that the current Board member, President and Chief Executive Officer, Dr Ming Chu Hsu, has been elected as Chairman of the company's Board of Directors. Dr Hsu will succeed Mr Show Chung Ho, who will continue his role as a Member of the Committee and Director of the Board.

 

“Mr Ho's vision and support have been vital to TaiGen since its inception. We are all grateful for his past and continuing contributions,” said Dr Hsu. “My role as CEO with TaiGen's business and scientific teams has been extremely rewarding, and I welcome the Board's support in its decision to expand my duties to the position of Chairman. I look forward to working with my colleagues and fellow board members as we push forward our development programs and business plan.”

 

Dr Hsu founded TaiGen Biotechnology in 2001 as President and Chief Executive Officer, and has led TaiGen through a period of extraordinary growth. Dr Hsu was the founding director of the Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes and Program Leader of the National Science and Technology Program in Biotech/ Pharmaceutical Research in Taiwan. Before her return to Taiwan in 1998, Dr Hsu was Research Director for Oncology and Virology at Hoffmann La Roche USA.